Search

Your search keyword '"Bois, Andreas du"' showing total 49 results
Start Over Author "Bois, Andreas du"
49 results on '"Bois, Andreas du"'

4. 2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial

Author

Fotopoulou, Christina, primary, Sehouli, Jalid, additional, Vergote, Ignace, additional, Reuss, Alexander, additional, Leheurteur, Marianne, additional, Hilpert, Felix, additional, Savoye, Aude-Marie, additional, Greggi, Stefano, additional, Vernersson, Johanna, additional, Resch, Benoît, additional, Gatineau, Michel, additional, Levêque, Jean, additional, Zang, Rongyu, additional, Jensen, Pernille T, additional, Kim, Jae W, additional, Santiago, Domingo, additional, Raspagliesi, Francesco, additional, Peen, Ulla, additional, Bois, Andreas du, additional, and Harter, Philipp, additional

Published
2022
Full Text
View/download PDF

5. 2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs)

Author

Denkert, Carsten, primary, Romey, Marcel, additional, Swedlund, Brad, additional, Hattesohl, Akira, additional, Teply-Szymanski, Julia, additional, Kommoss, Stefan, additional, Kaiser, Kristin, additional, Staebler, Annette, additional, Bois, Andreas Du, additional, Grass, Albert, additional, Knappmeyer, Christiane, additional, Heitz, Florian, additional, Solimeno, Cara, additional, Harter, Philipp, additional, Marmé, Frederik, additional, Gaiser, Timo, additional, Neff, Chris, additional, Wagner, Uwe, additional, Timms, Kirsten M, additional, and Rodepeter, Fiona, additional

Published
2022
Full Text
View/download PDF

6. 2022-RA-1515-ESGO Impact of surgical staging on survival of low grade endometrioid ovarian cancer apparently confined to the ovary

Author

Bizzarri, Nicolò, primary, Imterat, Majdi, additional, Fruscio, Robert, additional, Perrone, Anna Myriam, additional, Mancari, Rosanna, additional, Traut, Alexander, additional, Rosati, Andrea, additional, Bois, Andreas du, additional, Ferrari, Debora, additional, de Iaco, Pierandrea, additional, Ergasti, Raffaella, additional, Ataseven, Beyhan, additional, Volontè, Silvia, additional, Tesei, Marco, additional, Perri, Maria Teresa, additional, Heitz, Florian, additional, Concin, Nicole, additional, Fanfani, Francesco, additional, Vizza, Enrico, additional, Scambia, Giovanni, additional, Harter, Philipp, additional, and Fagotti, Anna, additional

Published
2022
Full Text
View/download PDF

7. 2022-RA-420-ESGO Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC) – real world data of the german quality assurance project (QS Ovar of the AGO Study Group)

Author

Mahner, Sven, primary, Bois, Andreas du, additional, Pfisterer, Jacobus, additional, Hilpert, Felix, additional, Kerkmann, Markus, additional, Sehouli, Jalid, additional, de Gregorio, Nikolaus, additional, Hanker, Lars Ch, additional, Heitz, Florian, additional, Marmé, Frederik, additional, Wölber, Linn Lena, additional, Holtmann, Laura, additional, Elser, Gabriele, additional, Harter, Philipp, additional, and Study Group, AGO, additional

Published
2022
Full Text
View/download PDF

8. 2022-RA-211-ESGO Expression of the anti-angiogenic VEGF-A splice variant, VEGF-A165b, as predictive biomarker for bevacizumab treatment in advanced ovarian cancer patients

Author

Wimberger, Pauline, primary, Gerber, Mara Julia, additional, Pfisterer, Jacobus, additional, Füssel, Susanne, additional, Erdmann, Kati, additional, Link, Theresa, additional, Bois, Andreas du, additional, Kommos, Stefan, additional, Sehouli, Jalid, additional, Hilpert, Felix, additional, Burges, Alexander, additional, Park-Simon, Tjoung-Wong, additional, Belau, Antje, additional, Hanker, Lars, additional, Kimmig, Rainer, additional, de Gregorio, Nikolaus, additional, Schmalfeldt, Barbara, additional, Baumann, Klaus, additional, Schröder, Willibald, additional, and Kuhlmann, Jan Dominik, additional

Published
2022
Full Text
View/download PDF

9. 2022-RA-1533-ESGO Role of fertility sparing surgery in patients with borderline ovarian tumors

Author

Westermann, Timo, primary, Heitz, Florian, additional, Ataseven, Beyhan, additional, Pauly, Nina, additional, Moubarak, Malak, additional, Strojna, Aleksandra, additional, Kaiser, Sabrina, additional, Nicole, Concin, additional, Welz, Julia, additional, Vrentas, Vasileios, additional, Dagres, Timoleon, additional, Imterat, Majdi, additional, Plett, Helmut, additional, Traut, Alexander, additional, Bois, Andreas du, additional, and Harter, Philipp, additional

Published
2022
Full Text
View/download PDF

11. 2022-RA-800-ESGO AGO-OVAR 27: window-of-opportunity proof-of-concept, non-randomized, open-label phase ii trial of olaparib given alone or in combination with durvalumab prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer

Author

Marmé, Frederik, primary, Heitz, Florian, additional, Harter, Philipp, additional, Reuss, Alexander, additional, Kipkeew, Friederike, additional, Wimberger, Pauline, additional, Bronger, Holger, additional, Bois, Andreas du, additional, Sehouli, Jalid, additional, and Hilpert, Felix, additional

Published
2022
Full Text
View/download PDF

12. 2022-RA-798-ESGO Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II)

Author

Harter, Philipp, primary, Ataseven, Beyhan, additional, Burges, Alexander, additional, Reuss, Alexander, additional, Kommoss, Stefan, additional, Sehouli, Jalid, additional, Lampe, Björn, additional, Schmalfeldt, Barbara, additional, Wimberger, Pauline, additional, Witteler, Ralf, additional, Buderath, Paul, additional, Herwig, Uwe, additional, Bronger, Holger, additional, Emons, Günter, additional, Klar, Maximilian, additional, Hasenburg, Annette, additional, de Gregorio, Nikolaus, additional, Hilpert, Felix, additional, Bois, Andreas du, additional, and Mahner, Sven, additional

Published
2022
Full Text
View/download PDF

13. 2022-RA-285-ESGO Real world data of treatment and outcome of patients with early ovarian cancer (FIGO I) in Germany (QS Ovar of the AGO Study Group)

Author

Sehouli, Jalid, primary, Bois, Andreas du, additional, Pfisterer, Jacobus, additional, Hilpert, Felix, additional, Kerkmann, Markus, additional, Mahner, Sven, additional, de Gregorio, Nikolaus, additional, Hanker, Lars Ch, additional, Heitz, Florian, additional, Marmé, Frederik, additional, Wölber, Linn Lena, additional, Holtmann, Laura, additional, Polleis, Sandra, additional, Wimberger, Pauline, additional, Harter, Philipp, additional, and Study Group, AGO, additional

Published
2022
Full Text
View/download PDF

15. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci

Author

Coetzee, Simon G., Shen, Howard C., Hazelett, Dennis J., Lawrenson, Kate, Kuchenbaecker, Karoline, Tyrer, Jonathan, Rhie, Suhn K., Levanon, Keren, Karst, Alison, Drapkin, Ronny, Ramus, Susan J., Couch, Fergus J., Offit, Kenneth, Chenevix-Trench, Georgia, Monteiro, Alvaro N.A., Antoniou, Antonis, Freedman, Matthew, Coetzee, Gerhard A., Pharoah, Paul D.P., Noushmehr, Houtan, Gayther, Simon A., Tyrer, Jonathan, Anton-Culver, Hoda, Antonenkova, Natalia, Baker, Helen, Bandera, Elisa V., Bean, Yukie, Beckmann, Matthias W., Berchuck, Andrew, Bisogna, Maria, Bjorge, Line, Bogdanova, Natalia, Brinton, Louise A., Brooks-Wilson, Angela, Bruinsma, Fiona, Butzow, Ralf, Campbell, Ian G., Carty, Karen, Chang-Claude, Jenny, Chen, Ann, Chen, Zhihua, Cook, Linda S., Cramer, Daniel W., Cunningham, Julie M., Cybulski, Cezary, Dansonka-Mieszkowska, Agnieszka, Dennis, Joe, Dicks, Ed, Doherty, Jennifer A., Dörk, Thilo, Bois, Andreas du, Dürst, Matthias, Eccles, Diana, Easton, Douglas F., Edwards, Robert P., Eilber, Ursula, Ekici, Arif B., Fasching, Peter A., Fridley, Brooke L., Gao, Yu-Tang, Gentry-Maharaj, Aleksandra, Giles, Graham G., Glasspool, Rosalind, Goode, Ellen L., Goodman, Marc T., Grownwald, Jacek, Harrington, Patricia, Harter, Philipp, Hasmad, Hanis Nazihah, Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle A.T., Hillemanns, Peter, Hogdall, Estrid, Hogdall, Claus, Hosono, Satoyo, Iversen, Edwin S., Jakubowska, Anna, James, Paul, Jensen, Allan, Ji, Bu-Tian, Karlan, Beth Y, Kjaer, Susanne Kruger, Kelemen, Linda E., Kellar, Melissa, Kelley, Joseph L., Kiemeney, Lambertus A., Krakstad, Camilla, Kupryjanczyk, Jolanta, Lambrechts, Diether, Lambrechts, Sandrina, Le, Nhu D., Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A., Liang, Dong, Lissowska, Jolanta, Lu, Karen, Lubinski, Jan, Lundvall, Lene, Massuger, Leon F.A.G., Matsuo, Keitaro, McGuire, Valerie, McLaughlin, John R., McNeish, Ian, Menon, Usha, Modugno, Francesmary, Moysich, Kirsten B., Narod, Steven A., Nedergaard, Lotte, Ness, Roberta B., Azmi, Mat Adenan Noor, Odunsi, Kunle, Olson, Sara H., Orlow, Irene, Orsulic, Sandra, Weber, Rachel Palmieri, Pearce, Celeste L., Pejovic, Tanja, Pelttari, Liisa M., Permuth-Wey, Jennifer, Phelan, Catherine M., Pike, Malcolm C., Poole, Elizabeth M., Risch, Harvey A., Rosen, Barry, Rossing, Mary Anne, Rothstein, Joseph H., Rudolph, Anja, Runnebaum, Ingo B., Rzepecka, Iwona K., Salvesen, Helga B., Schildkraut, Joellen M., Schwaab, Ira, Sellers, Thomas A., Shu, Xiao-Ou, Shvetsov, Yurii B, Siddiqui, Nadeem, Sieh, Weiva, Song, Honglin, Southey, Melissa C., Sucheston, Lara, Tangen, Ingvild L., Teo, Soo-Hwang, Terry, Kathryn L., Thompson, Pamela J., Timorek, Agnieszka, Tsai, Ya-Yu, Tworoger, Shelley S., Tyrer, Jonathan, van Altena, Anne M., Van Nieuwenhuysen, Els, Vergote, Ignace, Vierkant, Robert A., Wang-Gohrke, Shan, Walsh, Christine, Wentzensen, Nicolas, Whittemore, Alice S., Wicklund, Kristine G., Wilkens, Lynne R., Woo, Yin-Ling, Wu, Xifeng, Wu, Anna H., Yang, Hannah, Zheng, Wei, and Ziogas, Argyrios

Published
2015
Full Text
View/download PDF

16. Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial

Author

Schouten, Philip C., Richters, Lisa, Vis, Daniel J., Kommoss, Stefan, Dijk, Ewald Van, Ernst, Corinna, Kluin, Roelof J.C., Marm, Frederik M., Lips, Esther H., Schmidt, Sandra, Scheerman, Esther, Prieske, Katharina, Deurzen, Carolien H.M.Van, Burges, Alexander, Ewing-Graham, Patricia C., Dietrich, Dimo, Jager, Agnes, Gregorio, Nikolaus De, Hauke, Jan, Bois, Andreas Du, Nederlof, Petra M., Wessels, Lodewyk F., Hahnen, Eric, Harter, Philipp, Linn, Sabine C., Schmutzle, Rita K., Schouten, Philip C., Richters, Lisa, Vis, Daniel J., Kommoss, Stefan, Dijk, Ewald Van, Ernst, Corinna, Kluin, Roelof J.C., Marm, Frederik M., Lips, Esther H., Schmidt, Sandra, Scheerman, Esther, Prieske, Katharina, Deurzen, Carolien H.M.Van, Burges, Alexander, Ewing-Graham, Patricia C., Dietrich, Dimo, Jager, Agnes, Gregorio, Nikolaus De, Hauke, Jan, Bois, Andreas Du, Nederlof, Petra M., Wessels, Lodewyk F., Hahnen, Eric, Harter, Philipp, Linn, Sabine C., and Schmutzle, Rita K.

Abstract

Purpose: Previously, we developed breast cancer BRCA1-like and BRCA2-like copy-number profile shrunken centroid classifiers predictive for mutation status and response to therapy, targeting homologous recombination deficiency (HRD). Therefore, we investigated BRCA1- and BRCA2-like classification in ovarian cancer, aiming to acquire classifiers with similar properties as those in breast cancer. Experimental Design: We analyzed DNA copy-number profiles of germline BRCA1- and BRCA2-mutant ovarian cancers and control tumors and observed that existing breast cancer classifiers did not sufficiently predict mutation status. Hence, we trained new shrunken centroid classifiers on this set and validated them in the independent The Cancer Genome Atlas dataset. Subsequently, we assessed BRCA1/2-like classification and obtained germline and tumor mutation and methylation status of cancer predisposition genes, among them several involved in HR repair, of 300 ovarian cancer samples derived from the consecutive cohort trial AGO-TR1 (NCT02222883). Results: The detection rate of the BRCA1-like classifier for BRCA1 mutations and promoter hypermethylation was 95.6%. The BRCA2-like classifier performed less accurately, likely due to a smaller training set. Furthermore, three quarters of the BRCA1/ 2-like tumors could be explained by (epi)genetic alterations in BRCA1/2, germline RAD51C mutations and alterations in other genes involved in HR. Around half of the non-BRCA-mutated ovarian cancer cases displayed a BRCA-like phenotype. Conclusions: The newly trained classifiers detected most BRCAmutated and methylated cancers and all tumors harboring a RAD51C germline mutations. Beyond that, we found an additional substantial proportion of ovarian cancers to be BRCA-like. _2021 The Authors; Published by the American Association for Cancer Research.

Published
2021

17. A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer

Author

Salminen, Liina, primary, Braicu, Elena Ioana, additional, Lääperi, Mitja, additional, Jylhä, Antti, additional, Oksa, Sinikka, additional, Hietanen, Sakari, additional, Sehouli, Jalid, additional, Kulbe, Hagen, additional, Bois, Andreas du, additional, Mahner, Sven, additional, Harter, Philipp, additional, Carpén, Olli, additional, Huhtinen, Kaisa, additional, Hynninen, Johanna, additional, and Hilvo, Mika, additional

Published
2021
Full Text
View/download PDF

18. Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

Author

Harter, Philipp, Bois, Andreas du, Hahmann, Maik, Hasenburg, Annette, Burges, Alexander, Loibl, Sibylle, Gropp, Martina, Huober, Jens, Fink, Daniel, Schröder, Willibald, Muenstedt, Karsten, Schmalfeldt, Barbara, Emons, Guenter, Pfisterer, Jacobus, Wollschlaeger, Kerstin, Meerpohl, Hans-Gerd, Breitbach, Georg-Peter, Tanner, Berno, and Sehouli, Jalid

Published
2006
Full Text
View/download PDF

20. Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey

Author

Greggi, Stefano, Falcone, Francesca, Scaffa, Cono, Bois, Andreas du, Samartzis, Eleftherios Pierre Pierre, Pujade-Lauraine, Eric, Altena, A.M. van, Vergote, I., Martin, Antonio Gonzalez, Greggi, Stefano, Falcone, Francesca, Scaffa, Cono, Bois, Andreas du, Samartzis, Eleftherios Pierre Pierre, Pujade-Lauraine, Eric, Altena, A.M. van, Vergote, I., and Martin, Antonio Gonzalez

Abstract

Item does not contain fulltext

Published
2020

24. Abstract 2215: Detection of novel markers of transitional cell carcinoma of the ovary, the TCC-like variant of high grade serous carcinoma, using proteomics and immunohistochemistry

Author

Tessier-Cloutier, Basile, primary, Magrill, Jamie, additional, Kommoss, Stefan, additional, Gilks, Blake C., additional, Huntsman, David G., additional, Cochrane, Dawn R., additional, Talhouk, Aline, additional, Soslow, Robert, additional, Morin, Gregg B., additional, Hughes, Chris J., additional, Karnezis, Anthony N., additional, Chow, Christine, additional, Cheng, Angela S., additional, Bois, Andreas du, additional, Pfisterer, Jacobus, additional, and Kommoss, Friedrich, additional

Published
2017
Full Text
View/download PDF

25. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial

Author

Bois, Andreas du, Kristensen, Gunnar, Ray Coquard, Isabelle, Reuss, Alexander, Pignata, Sandro, Colombo, Nicoletta, Denison, Ursula, Vergote, Ignace, del Campo, Jose M, Ottevanger, Petronella, Heubner, Martin, Minarik, Thoma, Sevin, Emmanuel, de Gregorio, Nikolau, Bidziński, Mariusz, Pfisterer, Jacobu, Malander, Susanne, Hilpert, Felix, Mirza, Mansoor R, Scambia, Giovanni, Meier, Werner, Nicoletto, Maria O, Bjørge, Line, Lortholary, Alain, Sailer, Martin Oliver, Merger, Michael, Harter, Philipp, Scambia, Giovanni (ORCID:0000-0003-2758-1063), Bois, Andreas du, Kristensen, Gunnar, Ray Coquard, Isabelle, Reuss, Alexander, Pignata, Sandro, Colombo, Nicoletta, Denison, Ursula, Vergote, Ignace, del Campo, Jose M, Ottevanger, Petronella, Heubner, Martin, Minarik, Thoma, Sevin, Emmanuel, de Gregorio, Nikolau, Bidziński, Mariusz, Pfisterer, Jacobu, Malander, Susanne, Hilpert, Felix, Mirza, Mansoor R, Scambia, Giovanni, Meier, Werner, Nicoletto, Maria O, Bjørge, Line, Lortholary, Alain, Sailer, Martin Oliver, Merger, Michael, Harter, Philipp, and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

Background: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer. Methods: In this double-blind phase 3 trial, chemotherapy-naive patients (aged 18 years or older) with International Federation of Gynecology and Obstetrics (FIGO) IIB-IV ovarian cancer and upfront debulking surgery were stratified by postoperative resection status, FIGO stage, and planned carboplatin dose. Patients were randomly assigned (2:1) via an interactive voice or web-based response system to receive six cycles of carboplatin (AUC 5 mg/mL per min or 6 mg/mL per min) and paclitaxel (175 mg/m2) in addition to either 200 mg of nintedanib (nintedanib group) or placebo (placebo group) twice daily on days 2-21 of every 3-week cycle for up to 120 weeks. Patients, investigators, and independent radiological reviewers were masked to treatment allocation. The primary endpoint was investigator-assessed progression-free survival analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01015118. Findings: Between Dec 9, 2009, and July 27, 2011, 1503 patients were screened and 1366 randomly assigned by nine study groups in 22 countries: 911 to the nintedanib group and 455 to the placebo group. 486 (53%) of 911 patients in the nintedanib group experienced disease progression or death compared with 266 (58%) of 455 in the placebo group. Median progression-free survival was significantly longer in the nintedanib group than in the placebo group (17·2 months [95% CI 16·6-19·9] vs 16·6 months [13·9-19·1]; hazard ratio 0·84 [95% CI 0·72-0·98]; p=0·024). The most common adverse events were gastrointestinal

Published
2016

26. Is Neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery?

Author

Marth, Christian, Zeimet, Alain, and Bois, Andreas Du

Subjects
Cancer -- Adjuvant treatment, Ovarian cancer -- Care and treatment -- Drug therapy -- Research, Health
Abstract

Surgical debulking of epithelial ovarian carcinoma has been a mainstay of therapy for more than 50 years--since the approach was first advocated by Meigs in 1934. [1] In 1968, Munnell [...]

Published
2011

27. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer : randomized clinical trial

Author

AGO Breast Study Group, Möbus, Volker, Jackisch, Christian, Schneeweiss, Andreas, Huober, Jens, Lueck, Hans-Joachim, Bois, Andreas du, Thomssen, Christoph, Kurbacher, Christian M., Kuhn, Walther, Nitz, Ulrike, Runnebaum, Ingo B., Hinke, Axel, Kreienberg, Rolf, Untch, Michael, AGO Breast Study Group, Möbus, Volker, Jackisch, Christian, Schneeweiss, Andreas, Huober, Jens, Lueck, Hans-Joachim, Bois, Andreas du, Thomssen, Christoph, Kurbacher, Christian M., Kuhn, Walther, Nitz, Ulrike, Runnebaum, Ingo B., Hinke, Axel, Kreienberg, Rolf, and Untch, Michael

Abstract

BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin/cyclophosphamide followed by paclitaxel (EC→T) (every 3 weeks) as adjuvant treatment in high-risk breast cancer patients. The objective of this study was to evaluate the safety and efficacy of epoetin alfa in a second randomization of the intense dose-dense arm. METHODS: One thousand two hundred eighty-four patients were enrolled; 658 patients were randomly assigned to the IDD-ETC treatment group. Within the IDD-ETC group, 324 patients were further randomly assigned to the epoetin alfa group, and 319 were randomly assigned to the non-erythropoiesis-stimulating agent (ESA) control group. Primary efficacy endpoints included change in hemoglobin level from baseline to Cycle 9 and the percentage of subjects requiring red blood cell transfusion. Relapse-free survival, overall survival, and intramammary relapse were secondary endpoints estimated with Kaplan-Meier and Cox regression methods. Except for the primary hypothesis, all statistical tests were two-sided. RESULTS: Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001). The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm. After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse. CONCLUSIONS: Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival. However, epoetin alfa had an adverse effect, resulting in increased thrombosis.

Published
2013

28. Abstract B14: Rapid RNA-based histotyping of ovarian carcinomas

Author

Anglesio, Michael S., primary, Talhouk, Aline, additional, Kalloger, Steve E., additional, Haffari, Gholamreza, additional, Mackenzie, Robertson, additional, Cheung, Martin, additional, Senz, Janine, additional, Chow, Christine, additional, Lau, Sherman, additional, Intermaggio, Maria, additional, Ramus, Susan J., additional, Bois, Andreas du, additional, Pfisterer, Jacobus, additional, McAlpine, Jessica N., additional, Kommoss, Friedrich, additional, Gilks, Blake, additional, Kommoss, Stefan, additional, and Huntsman, David G., additional

Published
2013
Full Text
View/download PDF

30. A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Author

Perren, Timothy J., primary, Swart, Ann Marie, additional, Pfisterer, Jacobus, additional, Ledermann, Jonathan A., additional, Pujade-Lauraine, Eric, additional, Kristensen, Gunnar, additional, Carey, Mark S., additional, Beale, Philip, additional, Cervantes, Andrés, additional, Kurzeder, Christian, additional, Bois, Andreas du, additional, Sehouli, Jalid, additional, Kimmig, Rainer, additional, Stähle, Anne, additional, Collinson, Fiona, additional, Essapen, Sharadah, additional, Gourley, Charlie, additional, Lortholary, Alain, additional, Selle, Frédéric, additional, Mirza, Mansoor R., additional, Leminen, Arto, additional, Plante, Marie, additional, Stark, Dan, additional, Qian, Wendi, additional, Parmar, Mahesh K.B., additional, and Oza, Amit M., additional

Published
2011
Full Text
View/download PDF

39. Transvaginal sonography of myometrial invasion depth in endometrial cancer

Author

Prompeler, Heinrich, Madjar, Helmut, Bois, Andreas du, Lattermann, Ulrich, Wilhelm, Christian, Kommoss, Friedrich, and Pfleiderer, Albrecht

Abstract

The myometrial invasion depth of endometrial cancer is an important prognostic factor. The preoperative assessment is decisive for the appropriate surgical treatment. In 96 patients with endometrial cancer, the myometrial invasion depth (greater than 50% or less than 50%) was measured preoperatively using transvaginal sonography (TVS). The sonographic results were compared to the histopathological findings. A sensitivity of 93% was obtained for invasion depths greater than 50%. The predictive value of an invasion depth less than 50% was 93% as well. In 16% of the cases the invasion depth was overestimated while, in only 3% it was underestimated. The diagnostic accuracy was 81%. Forty-five patients were examined preceding a diagnostic dilatation and curettage and fifty-one were examined following a diagnostic dilatation and curettage. The diagnostic accuracy in both groups was equivalent. Using transvaginal sonography, the spread of cancer to the cervix was observed in five of the seven cases in which it was postoperatively confirmed.TVS is a valuable, non-invasive diagnostic method for patients with endometrial cancer. When the TVS data are combined with results from other preoperative tests, the prognostic information obtained provides a useful basis in choosing the appropriate therapy.

Published
1994
Full Text
View/download PDF

40. Comparison of the Emetogenic Potential Between Cisplatin and Carboplatin in Combination with Alkylating Agents

Author

Bois, Andreas du, Vach, Werner, Thomssen, Christoph, Karck, Ulrich, Madjar, Helmut, Prömpeler, Heiner, and Meerpohl, Hans

Abstract

Platinum-based poh chemotherapy is widely used in the treatment of gynecological cancer. Emesis is one of the most disturbing side-effects of platinum therapy. We performed a study to evaluate and compare the emetogenic potential and the different emesis pattern after cisplatin and carboplatin under antiemetic treatment with ondansetron. One hundred and twenty-two patients with either cisplatin-con-taining (n = 70) or carboplatin-containing (n = 52) first-line chemotherapy were included. Treatment with cisplatin led more frequently to emesis and patients suffered from more severe emesis than carboplatin treated patients. Delayed emesis was observed after both platinum analogues but occurred more frequently and lasted longer after cisplatin.

Published
1994
Full Text
View/download PDF

41. Twin pregnancies with single fetal death

Author

Prömpeler, Heinrich, Madjar, Helmut, Klosa, Wolfgang, Bois, Andreas du, Zahradnik, Hans, Schillinger, Helmut, and Breckwoldt, Meinert

Abstract

Objective. Analysis of the fetal outcome of the surviving twin and the cause of fetal death. Patients. Between January 1979 and December 1992, 43 twin pregnancies with single fetal death were observed: in 11 cases (group I) before 16 weeks of gestation, in 11 cases (group II) between 17 and 24 weeks, and in 21 cases (group III) after 24 weeks of gestation.Results. The pregnancies in group I continued without complication. In groups II and III the incidence of preterm delivery was 50%, of cesarean section 59%, of growth retardation of the surviving twin 22% and perinatal mortality was 13%. Twenty-five (78%) of the surviving twins had a normal postnatal development and one (3%) was handicapped.Conclusion. Loss of one of the twins in the first trimester does not impair the development of the surviving fetus. In the second trimester however this event is associated with increased risk for the survivor as reflected by a high incidence of growth retardation, premature labor and perinatal mortality.

Published
1994
Full Text
View/download PDF

42. Additional file 2: Table S2. of Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Author

Pulford, David, Harter, Philipp, Floquet, Anne, Barrett, Catherine, Suh, Dong, Friedlander, Michael, JosĂŠ Arranz, Kosei Hasegawa, Hiroomi Tada, Vuylsteke, Peter, Mirza, Mansoor, Donadello, Nicoletta, Scambia, Giovanni, Johnson, Toby, Cox, Charles, Chan, John, Imhof, Martin, Herzog, Thomas, Calvert, Paula, Wimberger, Pauline, Berton-Rigaud, Dominique, Lim, Myong, Elser, Gabriele, Xu, Chun-Fang, and Bois, Andreas Du

Subjects
3. Good health
Abstract

Shows the countries and respective populations that were involved in AGO-OVAR 16. (DOC 28 kb)

43. Additional file 1: Table S1. of Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Author

Pulford, David, Harter, Philipp, Floquet, Anne, Barrett, Catherine, Suh, Dong, Friedlander, Michael, JosĂŠ Arranz, Kosei Hasegawa, Hiroomi Tada, Vuylsteke, Peter, Mirza, Mansoor, Donadello, Nicoletta, Scambia, Giovanni, Johnson, Toby, Cox, Charles, Chan, John, Imhof, Martin, Herzog, Thomas, Calvert, Paula, Wimberger, Pauline, Berton-Rigaud, Dominique, Lim, Myong, Elser, Gabriele, Xu, Chun-Fang, and Bois, Andreas Du

Subjects
3. Good health
Abstract

Lists names and affiliations of local Institutional Review Boards and Independent Ethics Committees that approved the study. (PDF 211 kb)

44. Additional file 3: of Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Author

Pulford, David, Harter, Philipp, Floquet, Anne, Barrett, Catherine, Suh, Dong, Friedlander, Michael, JosĂŠ Arranz, Kosei Hasegawa, Hiroomi Tada, Vuylsteke, Peter, Mirza, Mansoor, Donadello, Nicoletta, Scambia, Giovanni, Johnson, Toby, Cox, Charles, Chan, John, Imhof, Martin, Herzog, Thomas, Calvert, Paula, Wimberger, Pauline, Berton-Rigaud, Dominique, Lim, Myong, Elser, Gabriele, Xu, Chun-Fang, and Bois, Andreas Du

Subjects
3. Good health
Abstract

Letter from GSK and the Trial Steering Committee to investigators who participated in AGO-OVAR 16. The letter outlines actions to be taken by GSK and those that are required by the investigators. (PDF 956 kb)

45. Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

Author

Dareng, Eileen O, Tyrer, Jonathan, Barnes, Daniel, Jones, Michelle R, Yang, Xin, Aben, Katja KH, Adank, Muriel A, Agata, Simona, Andrulis, Irene L, Anton-Culver, Hoda, Antonenkova, Natalia N, Aravantinos, Gerasimos, Arun, Banu K, Augustinsson, Annelie, Balma��a, Judith, Bandera, Elisa V, Barkardottir, Rosa B, Barrowdale, Daniel, Beckmann, Matthias W, Beeghly-Fadiel, Alicia, Benitez, Javier, Bermisheva, Marina, Bernardini, Marcus Q, Bjorge, Line, Black, Amanda, Bogdanova, Natalia V, Bonanni, Bernardo, Borg, Ake, Brenton, James, Budzilowska, Agnieszka, Butzow, Ralf, Buys, Saundra S, Cai, Hui, Caligo, Maria A, Campbell, Ian, Cannioto, Rikki, Cassingham, Hayley, Chang-Claude, Jenny, Chanock, Stephen J, Chen, Kexin, Chiew, Yoke-Eng, Chung, Wendy K, Claes, Kathleen BM, Colanna, Sarah, Cook, Linda S, Couch, Fergus J, Daly, Mary B, Dao, Fanny, Davies, Eleanor, De La Hoya, Miguel, Putter, Robin De, Dennis, Joe, DePersia, Allison, Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Doherty, Jennifer A, Domchek, Susan M, D��rk, Thilo, Bois, Andreas Du, D��rst, Matthias, Eccles, Diana M, Eliassen, Heather A, Engel, Christoph, Evans, D Gareth, Fasching, Peter A, Flanagan, James M, Foretova, Lenka, Fortner, Ren��e T, Friedman, Eitan, Ganz, Patricia A, Garber, Judy, Gensini, Francesca, Giles, Graham G, Glendon, Gord, Godwin, Andrew K, Goodman, Marc T, Greene, Mark H, Gronwald, Jacek, Hahnen, Eric, Haiman, Christopher A, H��kansson, Niclas, Hamann, Ute, Hansen, Thomas VO, Harris, Holly R, Hartman, Mikael, Heitz, Florian, Hildebrandt, Michelle AT, H��gdall, Estrid, H��gdall, Claus K, Hopper, John L, Huang, Ruea-Yea, Huff, Chad, Hulick, Peter J, Huntsman, David G, Imyanitov, Evgeny N, Isaacs, Claudine, Jakubowska, Anna, James, Paul A, Janavicius, Ramunas, Jensen, Allan, Johannsson, Oskar Th, John, Esther M, Jones, Michael E, Kang, Daehee, Karlan, Beth Y, Karnezis, Anthony, Kelemen, Linda E, Khusnutdinova, Elza, Kiemeney, Lambertus A, Kim, Byoung-Gie, Kjaer, Susanne K, Komenaka, Ian, Kupryjanczyk, Jolanta, Kurian, Allison W, Kwong, Ava, Lambrechts, Diether, Larson, Melissa C, Lazaro, Conxi, Le, Nhu D, Leslie, Goska, Lester, Jenny, Lesueur, Fabienne, Levine, Douglas A, Li, Lian, Li, Jingmei, Loud, Jennifer T, Lu, Karen H, Lubi��ski, Jan, Machackova, Eva, Mai, Phuong L, Manoukian, Siranoush, Marks, Jeffrey R, Matsuno, Rayna Kim, Matsuo, Keitaro, May, Taymaa, McGuffog, Lesley, McLaughlin, John R, McNeish, Iain A, Mebirouk, Noura, Menon, Usha, Miller, Austin, Milne, Roger L, Minlikeeva, Albina, Modugno, Francesmary, Montagna, Marco, Moysich, Kirsten B, Munro, Elizabeth, Nathanson, Katherine L, Neuhausen, Susan L, Nevanlinna, Heli, Yie, Joanne Ngeow Yuen, Nielsen, Henriette Roed, Nielsen, Finn C, Nikitina-Zake, Liene, Odunsi, Kunle, Offit, Kenneth, Olah, Edith, Olbrecht, Siel, Olopade, Olufunmilayo I, Olson, Sara H, Olsson, H��kan, Osorio, Ana, Papi, Laura, Park, Sue K, Parsons, Michael T, Pathak, Harsha, Pedersen, Inge Sokilde, Peixoto, Ana, Pejovic, Tanja, Perez-Segura, Pedro, Permuth, Jennifer B, Peshkin, Beth, Peterlongo, Paolo, Piskorz, Anna, Prokofyeva, Darya, Radice, Paolo, Rantala, Johanna, Riggan, Marjorie J, Risch, Harvey A, Rodriguez-Antona, Cristina, Ross, Eric, Rossing, Mary Anne, Runnebaum, Ingo, Sandler, Dale P, Santamari��a, Marta, Soucy, Penny, Schmutzler, Rita K, Setiawan, V Wendy, Shan, Kang, Sieh, Weiva, Simard, Jacques, Singer, Christian F, Sokolenko, Anna P, Song, Honglin, Southey, Melissa C, Steed, Helen, Stoppa-Lyonnet, Dominique, Sutphen, Rebecca, Swerdlow, Anthony J, Tan, Yen Yen, Teixeira, Manuel R, Teo, Soo Hwang, Terry, Kathryn L, Terry, Mary Beth, Thomassen, Mads, Thompson, Pamela J, Vestrheim Thomsen, Liv Cecilie, Thull, Darcy L, Tischkowitz, Marc, Titus, Linda, Toland, Amanda E, Torres, Diana, Trabert, Britton, Travis, Ruth, Tung, Nadine, Tworoger, Shelley S, Valen, Ellen, Van Altena, Anne M, Van Der Hout, Annemieke H, Van Nieuwenhuysen, Els, Van Rensburg, Elizabeth J, Vega, Ana, Edwards, Digna Velez, Vierkant, Robert A, Wang, Frances, Wappenschmidt, Barbara, Webb, Penelope M, Weinberg, Clarice R, Weitzel, Jeffrey N, Wentzensen, Nicolas, White, Emily, Whittemore, Alice S, Winham, Stacey J, Wolk, Alicja, Woo, Yin-Ling, Wu, Anna H, Yan, Li, Yannoukakos, Drakoulis, Zavaglia, Katia M, Zheng, Wei, Ziogas, Argyrios, Zorn, Kristin K, Easton, Douglas, Lawrenson, Kate, DeFazio, Anna, Sellers, Thomas A, Ramus, Susan J, Pearce, Celeste L, Monteiro, Alvaro N, Cunningham, Julie, Goode, Ellen L, Schildkraut, Joellen M, Berchuck, Andrew, Chenevix-Trench, Georgia, Gayther, Simon A, Antoniou, Antonis C, and Pharoah, Paul DP

Subjects
3. Good health
Abstract

Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally-efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, ���select and shrink for summary statistics��� (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestry; 7,669 women of East Asian ancestry; 1,072 women of African ancestry, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestry. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38(95%CI:1.28���1.48,AUC:0.588) per unit standard deviation, in women of European ancestry; 1.14(95%CI:1.08���1.19,AUC:0.538) in women of East Asian ancestry; 1.38(95%CI:1.21-1.58,AUC:0.593) in women of African ancestry; hazard ratios of 1.37(95%CI:1.30���1.44,AUC:0.592) in BRCA1 pathogenic variant carriers and 1.51(95%CI:1.36-1.67,AUC:0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

46. Additional file 1: Table S1. of Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Author

Pulford, David, Harter, Philipp, Floquet, Anne, Barrett, Catherine, Suh, Dong, Friedlander, Michael, JosĂŠ Arranz, Kosei Hasegawa, Hiroomi Tada, Vuylsteke, Peter, Mirza, Mansoor, Donadello, Nicoletta, Scambia, Giovanni, Johnson, Toby, Cox, Charles, Chan, John, Imhof, Martin, Herzog, Thomas, Calvert, Paula, Wimberger, Pauline, Berton-Rigaud, Dominique, Lim, Myong, Elser, Gabriele, Xu, Chun-Fang, and Bois, Andreas Du

Subjects
3. Good health
Abstract

Lists names and affiliations of local Institutional Review Boards and Independent Ethics Committees that approved the study. (PDF 211 kb)

47. Additional file 3: of Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Author

Pulford, David, Harter, Philipp, Floquet, Anne, Barrett, Catherine, Suh, Dong, Friedlander, Michael, JosĂŠ Arranz, Kosei Hasegawa, Hiroomi Tada, Vuylsteke, Peter, Mirza, Mansoor, Donadello, Nicoletta, Scambia, Giovanni, Johnson, Toby, Cox, Charles, Chan, John, Imhof, Martin, Herzog, Thomas, Calvert, Paula, Wimberger, Pauline, Berton-Rigaud, Dominique, Lim, Myong, Elser, Gabriele, Xu, Chun-Fang, and Bois, Andreas Du

Subjects
3. Good health
Abstract

Letter from GSK and the Trial Steering Committee to investigators who participated in AGO-OVAR 16. The letter outlines actions to be taken by GSK and those that are required by the investigators. (PDF 956 kb)

48. Additional file 2: Table S2. of Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Author

Pulford, David, Harter, Philipp, Floquet, Anne, Barrett, Catherine, Suh, Dong, Friedlander, Michael, JosĂŠ Arranz, Kosei Hasegawa, Hiroomi Tada, Vuylsteke, Peter, Mirza, Mansoor, Donadello, Nicoletta, Scambia, Giovanni, Johnson, Toby, Cox, Charles, Chan, John, Imhof, Martin, Herzog, Thomas, Calvert, Paula, Wimberger, Pauline, Berton-Rigaud, Dominique, Lim, Myong, Elser, Gabriele, Xu, Chun-Fang, and Bois, Andreas Du

Subjects
3. Good health
Abstract

Shows the countries and respective populations that were involved in AGO-OVAR 16. (DOC 28 kb)

49. Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

Author

V. Wendy Setiawan, Ana Osorio, Liv Cecilie Vestrheim Thomsen, Francesca Gensini, Harsha Pathak, Barbara Wappenschmidt, Ingo B. Runnebaum, Javier Benitez, Rita K. Schmutzler, Jeffrey N. Weitzel, Yin Ling Woo, Kenneth Offit, Anthony N. Karnezis, Eitan Friedman, Jacques Simard, James M. Flanagan, Pedro Pérez-Segura, Siranoush Manoukian, Melissa C. Southey, Ramunas Janavicius, Finn Cilius Nielsen, Graham G. Giles, Usha Menon, Ava Kwong, Anna H. Wu, Thomas Hansen, Cristina Rodríguez-Antona, Maria A. Caligo, Argyrios Ziogas, Allison DePersia, Anna P. Sokolenko, Clarice R. Weinberg, Hoda Anton-Culver, Digna R. Velez Edwards, Jennifer B. Permuth, Patricia A. Ganz, Ana Vega, Keitaro Matsuo, Heli Nevanlinna, Frances Wang, Natalia Antonenkova, Claudine Isaacs, Conxi Lázaro, Melissa C. Larson, Henriette Roed Nielsen, Byoung-Gie Kim, Andreas du Bois, Dale P. Sandler, Anna Jakubowska, Paul D.P. Pharoah, Jenny Lester, Paolo Radice, Natalia Bogdanova, Lambertus A. Kiemeney, Mary Anne Rossing, Thilo Dörk, Ruea-Yea Huang, Judy Garber, Taymaa May, Diana Eccles, Mary Beth Terry, Jenny Chang-Claude, Jeffrey R. Marks, Dominique Stoppa-Lyonnet, Heather Eliassen, Douglas A. Levine, Phuong L. Mai, Gerasimos Aravantinos, Hui Cai, Britton Trabert, Amanda Black, Noura Mebirouk, Robin de Putter, Rayna K. Matsuno, Ralf Bützow, Joanne Ngeow Yuen Yie, James D. Brenton, Nadine Tung, Drakoulis Yannoukakos, Jonathan Tyrer, L Yan, Yen Y. Tan, Ian Komenaka, Simona Agata, Honglin Song, Tanja Pejovic, Marjorie J. Riggan, Antonis C. Antoniou, Katja K.H. Aben, Goska Leslie, Eric A. Ross, Estrid Høgdall, Kang Shan, Holly R. Harris, Eleanor Davies, Liene Nikitina-Zake, Florian Heitz, Stephen J. Chanock, Matthew Jones, Beth Y. Karlan, Matthias W. Beckmann, Penelope M. Webb, John L. Hopper, Peter A. Fasching, Jacek Gronwald, kConFab Investigators, Ana Peixoto, Joellen M. Schildkraut, Renée T. Fortner, Susan L. Neuhausen, Daehee Kang, Anthony J. Swerdlow, Lesley McGuffog, Marco Montagna, Paolo Peterlongo, Daniel R. Barnes, Marina Bermisheva, Alicja Wolk, Yuan Chun Ding, Marc Tischkowitz, Gord Glendon, Elza Khusnutdinova, Julie M. Cunningham, Saundra S. Buys, Albina N. Minlikeeva, Jennifer A. Doherty, Annemieke H. van der Hout, Austin Miller, Fergus J. Couch, Fabienne Lesueur, Peter Devilee, Kristin K. Zorn, Daniel Barrowdale, Christian F. Singer, Line Bjørge, Åke Borg, Diether Lambrechts, Shelley S. Tworoger, Allan Jensen, Ute Hamann, Douglas F. Easton, Bernardo Bonanni, Alvaro N.A. Monteiro, Johanna Rantala, Marc T. Goodman, Ellen Valen, Wei Zheng, Thomas A. Sellers, Marcus Q. Bernardini, Alice S. Whittemore, Kunle Odunsi, Inge Søkilde Pedersen, Laura Papi, Mads Thomassen, Allison W. Kurian, Emily White, Penny Soucy, D. Gareth Evans, Lenka Foretova, Kathryn L. Terry, Ruth C. Travis, Claus Høgdall, Hebon Investigators, Darya Prokofyeva, Stacey J. Winham, Yoke-Eng Chiew, Eileen Dareng, Jan Lubinski, Elizabeth Munro, Oskar T. Johannsson, Linda E. Kelemen, Kexin Chen, Xin Yang, Manuel R. Teixeira, Anna M. Piskorz, Edith Olah, Helen Steed, Beth N. Peshkin, Georgia Chenevix-Trench, Andrew K. Godwin, Pamela J. Thompson, Chad D. Huff, Rosa B. Barkardottir, Muriel A. Adank, Mikael Hartman, Linda J. Titus, Weiva Sieh, Simon A. Gayther, Peter J. Hulick, Michael T. Parsons, Elisa V. Bandera, Amanda E. Toland, Miguel de la Hoya, Orland Diez, Alicia Beeghly-Fadiel, Rebecca Sutphen, Francesmary Modugno, Judith Balmaña, Christoph Engel, Harvey A. Risch, Elizabeth J. van Rensburg, Michael Jones, Rikki Cannioto, Michelle A.T. Hildebrandt, Soo Hwang Teo, Fanny Dao, Susan J. Ramus, Sarah Colanna, Kathleen Claes, David G. Huntsman, Siel Olbrecht, Esther M. John, Robert A. Vierkant, Wendy K. Chung, Ellen L. Goode, Olufunmilayo I. Olopade, Evgeny N. Imyanitov, Joe Dennis, Andrew Berchuck, Banu Arun, Darcy L. Thull, Lian Li, Celeste Leigh Pearce, Sue K. Park, Susan M. Domchek, Agnieszka Budzilowska, Håkan Olsson, Susanne K. Kjaer, Mark H. Greene, Katia M. Zavaglia, Jolanta Kupryjanczyk, Nicolas Wentzensen, Karen H. Lu, Hayley Cassingham, Christopher A. Haiman, Eric Hahnen, Els Van Nieuwenhuysen, Katherine L. Nathanson, Anna deFazio, Ian G. Campbell, Paul A. James, Sara H. Olson, Eva Machackova, Anne M. van Altena, Irene L. Andrulis, Linda S. Cook, Matthias Dürst, Mary B. Daly, John R. McLaughlin, Niclas Håkansson, Jingmei Li, Diana Torres, Iain A. McNeish, Jennifer T. Loud, Roger L. Milne, Marta Santamariña, Annelie Augustinsson, Nhu D. Le, Kate Lawrenson, Kirsten B. Moysich, Dareng, Eileen O [0000-0003-0802-419X], Tyrer, Jonathan [0000-0003-3724-4757], Barnes, Daniel [0000-0002-3781-7570], Jones, Michelle R [0000-0001-5466-3844], Agata, Simona [0000-0002-6329-0768], Anton-Culver, Hoda [0000-0002-9603-0110], Augustinsson, Annelie [0000-0003-3415-0536], Bandera, Elisa V [0000-0002-8789-2755], Barkardottir, Rosa B [0000-0003-0629-2772], Brenton, James [0000-0002-5738-6683], Campbell, Ian [0000-0002-7773-4155], Chen, Kexin [0000-0003-1010-8093], Chung, Wendy K [0000-0003-3438-5685], Claes, Kathleen BM [0000-0003-0841-7372], Devilee, Peter [0000-0002-8023-2009], Diez, Orland [0000-0001-7339-0570], Bois, Andreas du [0000-0002-8477-506X], Eccles, Diana M [0000-0002-9935-3169], Eliassen, Heather A [0000-0002-3961-6609], Ganz, Patricia A [0000-0002-1841-4143], Giles, Graham G [0000-0003-4946-9099], Glendon, Gord [0000-0001-8630-6673], Greene, Mark H [0000-0003-1852-9239], Hartman, Mikael [0000-0001-5726-9965], Heitz, Florian [0000-0002-2412-0352], Isaacs, Claudine [0000-0002-9646-1260], Janavicius, Ramunas [0000-0002-3773-8485], John, Esther M [0000-0003-3259-8003], Kang, Daehee [0000-0003-4031-5878], Karlan, Beth Y [0000-0002-9451-2933], Khusnutdinova, Elza [0000-0003-2987-3334], Kjaer, Susanne K [0000-0002-8347-1398], Manoukian, Siranoush [0000-0002-6034-7562], Matsuo, Keitaro [0000-0003-1761-6314], Menon, Usha [0000-0003-3708-1732], Miller, Austin [0000-0001-9739-8462], Nikitina-Zake, Liene [0000-0003-2491-5187], Olbrecht, Siel [0000-0001-9452-5905], Olopade, Olufunmilayo I [0000-0002-9936-1599], Olson, Sara H [0000-0003-0182-2754], Papi, Laura [0000-0003-4552-9517], Park, Sue K [0000-0001-5002-9707], Parsons, Michael T [0000-0003-3242-8477], Permuth, Jennifer B [0000-0002-4726-9264], Peterlongo, Paolo [0000-0001-6951-6855], Radice, Paolo [0000-0001-6298-4111], Swerdlow, Anthony J [0000-0001-5550-4159], Toland, Amanda E [0000-0002-0271-1792], Webb, Penelope M [0000-0003-0733-5930], Weinberg, Clarice R [0000-0002-7713-8556], Weitzel, Jeffrey N [0000-0001-6714-092X], Winham, Stacey J [0000-0002-8492-9102], Wolk, Alicja [0000-0001-7387-6845], Yannoukakos, Drakoulis [0000-0001-7509-3510], Easton, Douglas [0000-0003-2444-3247], Ramus, Susan J [0000-0003-0005-7798], Chenevix-Trench, Georgia [0000-0002-1878-2587], and Apollo - University of Cambridge Repository

Subjects
Oncology, medicine.medical_specialty, 45/61, 45/43, Single-nucleotide polymorphism, Logistic regression, 631/208/2489, 03 medical and health sciences, 0302 clinical medicine, Lasso (statistics), Internal medicine, Genotype, medicine, SNP, 030304 developmental biology, 0303 health sciences, business.industry, Hazard ratio, article, Odds ratio, 631/208/721, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, business, Ovarian cancer, 692/499
Abstract

Funder: Funding details are provided in the Supplementary Material, Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally-efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, ���select and shrink for summary statistics��� (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestry; 7,669 women of East Asian ancestry; 1,072 women of African ancestry, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestry. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38(95%CI:1.28���1.48,AUC:0.588) per unit standard deviation, in women of European ancestry; 1.14(95%CI:1.08���1.19,AUC:0.538) in women of East Asian ancestry; 1.38(95%CI:1.21-1.58,AUC:0.593) in women of African ancestry; hazard ratios of 1.37(95%CI:1.30���1.44,AUC:0.592) in BRCA1 pathogenic variant carriers and 1.51(95%CI:1.36-1.67,AUC:0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results